About this Course
This course is a recorded (home study version) of the CE Finale Encore Webinars.
Upon completion of this application based CE Activity, a pharmacist will be able to:
|1. Discuss trends in the epidemiology of the COVID-19 pandemic and Monkeypox outbreak.|
|2. Discuss current clinical data on the safety and effectiveness of (i) the bivalent COVID-19 booster vaccines and (ii) the JYNNEOS or ACAM2000 vaccines for Monkeypox.|
|3. Explain whether a person would be eligible for receipt of (i) the bivalent COVID-19 booster vaccines and/or (ii) the JYNNEOS or ACAM2000 vaccines for Monkeypox.|
Release and Expiration Dates
Released: December 16, 2022
Expires: December 16, 2025
1.0 hours of CE
|The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs) for completing the activity ACPE UAN 0009-0000-22-059-H06-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.
Jeffery Aeschlimann, PharmD
Associate Clinical Professor-Infectious Disease Specialty
University of Connecticut School of Pharmacy
In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.
- Dr. Aeschlimann has no relationships with ineligible companies
The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
- Good news! News reporters and Internet sites began announcing in the spring and summer of 2022 that the global pandemic had ended. What do you think of that?
- YAY! Science prevailed and we obliterated that bad boy and sent it away!
- FAKE NEWS. Approximately 2,000 Americans still die each week from (or with) active COVID-19 disease.
- CORRECT, but COVID is still a major concern in our socially inclined young adults.
- What does the data say about adverse effects associated with the bivalent COVID-19 boosters?
- The most common adverse effects are systemic (fever, chills, fatigue)
- The most common adverse effects are central (headache, mental fogginess)
- The most common adverse effects are local (pain, erythema, swelling)
- Based on current vaccination statistics about populations that have the poorest booster coverage for COVID-19, which of the following population should pharmacists be encouraging to GET VACCINATED!?!
- Children age 5 or younger in the Great Lakes regions
- People older than 65 in the Pacific northwest
- Everybody everywhere
- Monkeypox is the name and name-changing is the game. What has the World Health organization decided to call this infection and why?
- It will be monk's disease, which will remove some of the stigmatizing language and remind people to live like a monk until the lesions disappear.
- It will be mpox, which is intended to dissuade people from using racist and stigmatizing language to describe people infected with this virus.
- It will be var-vac-human, reflecting its similarity to variola (smallpox) and vaccinia (viral vaccine for smallpox) and its zoonotic transmission.
- What is eczema vaccinatum?
- A complication of the ACAM2000 vaccination that can occur in patients who have eczema/atopic dermatitis, in which vaccinia virus disseminates to cause an extensive rash and systemic illness.
- A complication of the JYNNEOS vaccination that can occur in patients who have eczema/atopic dermatitis, in which vaccinia virus disseminates to cause an extensive rash and systemic illness.
- A complication of the ACAM2000 vaccination that can occur in patients who have any chronic skin condition, in which vaccinia virus disseminates to cause an extensive rash and systemic illness.
- Andi is a person living with HIV infection who also is prone to keloids. This patient wants the JYNNEOS vaccination for mpox. What is the best course of action?
- Administer the vaccine intradermally
- Administer the vaccine subcutaneously
- Recommend using ACAM2000 instead